Skip to main content
Erschienen in: Cellular Oncology 1/2021

10.09.2020 | Original paper

Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation

verfasst von: Geun-Young Park, Harsh B. Pathak, Andrew K. Godwin, Youngjoo Kwon

Erschienen in: Cellular Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Paracrine interactions with the stromal environment, including fibroblasts, may be important in the pathogenesis of ovarian cancer. Here, we evaluated the effect of conditioned media derived from ovarian fibroblasts (fibroblast-CMs) and their major cytokines on the growth of ovarian cancer cells, as well as the involvement of mitogen-activated protein kinases (MAPKs) and AKT in mediating this effect.

Methods

Ovarian cancer cells were cultured in serum-free media (SF), or conditioned media of fibroblasts derived from normal ovary (CM1) and ovarian tumor tissue (CM2). Cell proliferation was measured by MTT assay. Phosphorylation of MAPKs and AKT was evaluated by Western blotting. Specific inhibitors of MAPKs and AKT were used to evaluate their respective involvement in mediating increased cell growth. Cytokine levels in fibroblast-CMs were measured using Luminex assays. Immunohistochemical staining was conducted for CXCL1, CXCR2 and phosphorylated p38 in primary ovarian tumors.

Results

CM1 and CM2 significantly increased the growth of ovarian cancer cells relative to SF. In OVCAR3 and OVCAR4 cells, p38 phosphorylation was strongly induced by fibroblast-CMs, and pre-treatment with a p38 inhibitor prevented the growth increase induced by fibroblast-CMs. Fibroblasts secreted high levels of IL-6, IL-8, MCP1 and CXCL1. Treatment with only CXCL1 (1 μg/ml) increased cell growth and p38 phosphorylation. Treatment with a CXCR2 inhibitor effectively prevented p38 activation and cell growth induced by fibroblast-CMs. High expression of both CXCL1 and CXCR2 correlated with high expression of phosphorylated p38 in primary ovarian tumors.

Conclusions

From our data, we conclude that CXCL1 is a key factor derived from ovarian fibroblasts that is responsible for increased ovarian cancer cell growth in part through p38 activation. Phosphorylated p38 can be used as a biomarker to predict CXCL1-CXCR2 interaction in vivo.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRef F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRef
2.
Zurück zum Zitat L.C. Peres, K.L. Cushing-Haugen, M. Kobel, H.R. Harris, A. Berchuck, M.A. Rossing, J.M. Schildkraut, J.A. Doherty, Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl. Cancer Inst. 111(1), 60–68 (2019) L.C. Peres, K.L. Cushing-Haugen, M. Kobel, H.R. Harris, A. Berchuck, M.A. Rossing, J.M. Schildkraut, J.A. Doherty, Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl. Cancer Inst. 111(1), 60–68 (2019)
3.
Zurück zum Zitat R.J. Kurman, M. Shih Ie, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34(3), 433–443 (2010)CrossRef R.J. Kurman, M. Shih Ie, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34(3), 433–443 (2010)CrossRef
4.
Zurück zum Zitat Y. Kwon, A.K. Godwin, Regulation of HGF and c-MET interaction in normal ovary and ovarian cancer: Importance of targeting c-MET and HGF interaction. Reprod. Sci. 24(4), 494–501 (2016) Y. Kwon, A.K. Godwin, Regulation of HGF and c-MET interaction in normal ovary and ovarian cancer: Importance of targeting c-MET and HGF interaction. Reprod. Sci. 24(4), 494–501 (2016)
5.
Zurück zum Zitat M. Yousefi, S. Dehghani, R. Nosrati, M. Ghanei, A. Salmaninejad, S. Rajaie, M. Hasanzadeh, A. Pasdar, Current insights into the metastasis of epithelial ovarian cancer-hopes and hurdles. Cell. Oncol. 43(4), 515–538 (2020)CrossRef M. Yousefi, S. Dehghani, R. Nosrati, M. Ghanei, A. Salmaninejad, S. Rajaie, M. Hasanzadeh, A. Pasdar, Current insights into the metastasis of epithelial ovarian cancer-hopes and hurdles. Cell. Oncol. 43(4), 515–538 (2020)CrossRef
6.
Zurück zum Zitat R.J. Kurman, M. Shih Ie, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum. Pathol. 42(7), 918–931 (2011)CrossRef R.J. Kurman, M. Shih Ie, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum. Pathol. 42(7), 918–931 (2011)CrossRef
7.
Zurück zum Zitat I. Cass, C. Holschneider, N. Datta, D. Barbuto, A.E. Walts, B.Y. Karlan, BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet. Gynecol. 106(6), 1327–1334 (2005)CrossRef I. Cass, C. Holschneider, N. Datta, D. Barbuto, A.E. Walts, B.Y. Karlan, BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet. Gynecol. 106(6), 1327–1334 (2005)CrossRef
8.
Zurück zum Zitat B.K. Erickson, M.G. Conner, C.N. Landen Jr., The role of the fallopian tube in the origin of ovarian cancer. Am. J. Obstet. Gynecol. 209(5), 409–414 (2013)CrossRef B.K. Erickson, M.G. Conner, C.N. Landen Jr., The role of the fallopian tube in the origin of ovarian cancer. Am. J. Obstet. Gynecol. 209(5), 409–414 (2013)CrossRef
9.
Zurück zum Zitat S.H. George, R. Garcia, B.M. Slomovitz, Ovarian cancer: The fallopian tube as the site of origin and opportunities for prevention. Front. Oncol. 6, 108 (2016) S.H. George, R. Garcia, B.M. Slomovitz, Ovarian cancer: The fallopian tube as the site of origin and opportunities for prevention. Front. Oncol. 6, 108 (2016)
10.
Zurück zum Zitat S.I. Labidi-Galy, E. Papp, D. Hallberg, N. Niknafs, V. Adleff, M. Noe, R. Bhattacharya, M. Novak, S. Jones, J. Phallen, C.A. Hruban, M.S. Hirsch, D.I. Lin, L. Schwartz, C.L. Maire, J.C. Tille, M. Bowden, A. Ayhan, L.D. Wood, R.B. Scharpf, R. Kurman, T.L. Wang, I.M. Shih, R. Karchin, R. Drapkin, V.E. Velculescu, High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 8(1), 1093 (2017)CrossRef S.I. Labidi-Galy, E. Papp, D. Hallberg, N. Niknafs, V. Adleff, M. Noe, R. Bhattacharya, M. Novak, S. Jones, J. Phallen, C.A. Hruban, M.S. Hirsch, D.I. Lin, L. Schwartz, C.L. Maire, J.C. Tille, M. Bowden, A. Ayhan, L.D. Wood, R.B. Scharpf, R. Kurman, T.L. Wang, I.M. Shih, R. Karchin, R. Drapkin, V.E. Velculescu, High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 8(1), 1093 (2017)CrossRef
11.
Zurück zum Zitat T.R. Soong, B.E. Howitt, A. Miron, N.S. Horowitz, F. Campbell, C.M. Feltmate, M.G. Muto, R.S. Berkowitz, M.R. Nucci, W. Xian, C.P. Crum, Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J. Pathol. 246(3), 344–351 (2018)CrossRef T.R. Soong, B.E. Howitt, A. Miron, N.S. Horowitz, F. Campbell, C.M. Feltmate, M.G. Muto, R.S. Berkowitz, M.R. Nucci, W. Xian, C.P. Crum, Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J. Pathol. 246(3), 344–351 (2018)CrossRef
12.
Zurück zum Zitat P. Nilendu, S.C. Sarode, D. Jahagirdar, I. Tandon, S. Patil, G.S. Sarode, J.K. Pal, N.K. Sharma, Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell. Oncol. 41(4), 353–367 (2018)CrossRef P. Nilendu, S.C. Sarode, D. Jahagirdar, I. Tandon, S. Patil, G.S. Sarode, J.K. Pal, N.K. Sharma, Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell. Oncol. 41(4), 353–367 (2018)CrossRef
13.
Zurück zum Zitat A. Salmaninejad, S.F. Valilou, A. Soltani, S. Ahmadi, Y.J. Abarghan, R.J. Rosengren, A. Sahebkar, Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell. Oncol. 42(5), 591–608 (2019)CrossRef A. Salmaninejad, S.F. Valilou, A. Soltani, S. Ahmadi, Y.J. Abarghan, R.J. Rosengren, A. Sahebkar, Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell. Oncol. 42(5), 591–608 (2019)CrossRef
14.
Zurück zum Zitat Y. Kwon, B.D. Smith, Y. Zhou, M.D. Kaufman, A.K. Godwin, Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene 34(2), 144–153 (2015)CrossRef Y. Kwon, B.D. Smith, Y. Zhou, M.D. Kaufman, A.K. Godwin, Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene 34(2), 144–153 (2015)CrossRef
15.
Zurück zum Zitat Y. Cheng, X.L. Ma, Y.Q. Wei, X.W. Wei, Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim. Biophys. Acta Rev. Cancer 1871(2), 289–312 (2019) Y. Cheng, X.L. Ma, Y.Q. Wei, X.W. Wei, Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim. Biophys. Acta Rev. Cancer 1871(2), 289–312 (2019)
16.
Zurück zum Zitat Y. Lu, B. Dong, F. Xu, Y. Xu, J. Pan, J. Song, J. Zhang, Y. Huang, W. Xue, CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition. Cell. Commun. Signal. 17(1), 118 (2019) Y. Lu, B. Dong, F. Xu, Y. Xu, J. Pan, J. Song, J. Zhang, Y. Huang, W. Xue, CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition. Cell. Commun. Signal. 17(1), 118 (2019)
17.
Zurück zum Zitat A. Zou, D. Lambert, H. Yeh, K. Yasukawa, F. Behbod, F. Fan, N. Cheng, Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-beta signaling proteins. BMC Cancer 14, 781 (2014)CrossRef A. Zou, D. Lambert, H. Yeh, K. Yasukawa, F. Behbod, F. Fan, N. Cheng, Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-beta signaling proteins. BMC Cancer 14, 781 (2014)CrossRef
18.
Zurück zum Zitat K.V. Sawant, R. Xu, R. Cox, H. Hawkins, E. Sbrana, D. Kolli, R.P. Garofalo, K. Rajarathnam, Chemokine CXCL1-mediated neutrophil trafficking in the lung: Role of CXCR2 activation. J. Innate Immun. 7(6), 647–658 (2015) K.V. Sawant, R. Xu, R. Cox, H. Hawkins, E. Sbrana, D. Kolli, R.P. Garofalo, K. Rajarathnam, Chemokine CXCL1-mediated neutrophil trafficking in the lung: Role of CXCR2 activation. J. Innate Immun. 7(6), 647–658 (2015)
19.
Zurück zum Zitat K.V. Sawant, K.M. Poluri, A.K. Dutta, K.M. Sepuru, A. Troshkina, R.P. Garofalo, K. Rajarathnam, Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci. Rep. 6, 33123 (2016)CrossRef K.V. Sawant, K.M. Poluri, A.K. Dutta, K.M. Sepuru, A. Troshkina, R.P. Garofalo, K. Rajarathnam, Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci. Rep. 6, 33123 (2016)CrossRef
20.
Zurück zum Zitat C. Bolitho, M.A. Hahn, R.C. Baxter, D.J. Marsh, The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr. Relat. Cancer 17(4), 929–940 (2010)CrossRef C. Bolitho, M.A. Hahn, R.C. Baxter, D.J. Marsh, The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr. Relat. Cancer 17(4), 929–940 (2010)CrossRef
21.
Zurück zum Zitat K.Q. Han, H. Han, X.Q. He, L. Wang, X.D. Guo, X.M. Zhang, J. Chen, Q.G. Zhu, H. Nian, X.F. Zhai, M.W. Jiang, Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma. Cancer Med. 5(10), 2861–2871 (2016) K.Q. Han, H. Han, X.Q. He, L. Wang, X.D. Guo, X.M. Zhang, J. Chen, Q.G. Zhu, H. Nian, X.F. Zhai, M.W. Jiang, Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma. Cancer Med. 5(10), 2861–2871 (2016)
22.
Zurück zum Zitat B. Lu, Y. Zhou, Z. Su, A. Yan, P. Ding, Effect of CCL2 siRNA on proliferation and apoptosis in the U251 human glioma cell line. Mol. Med. Rep. 16(3), 3387–3394 (2017)CrossRef B. Lu, Y. Zhou, Z. Su, A. Yan, P. Ding, Effect of CCL2 siRNA on proliferation and apoptosis in the U251 human glioma cell line. Mol. Med. Rep. 16(3), 3387–3394 (2017)CrossRef
23.
Zurück zum Zitat X. Cui, Z. Li, J. Gao, P.J. Gao, Y.B. Ni, J.Y. Zhu, Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a. Oncotarget 7(40), 65052–65066 (2016)CrossRef X. Cui, Z. Li, J. Gao, P.J. Gao, Y.B. Ni, J.Y. Zhu, Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a. Oncotarget 7(40), 65052–65066 (2016)CrossRef
24.
Zurück zum Zitat W. Zhang, H.T. Liu, MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12(1), 9–18 (2002)CrossRef W. Zhang, H.T. Liu, MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12(1), 9–18 (2002)CrossRef
25.
Zurück zum Zitat Y. Sun, W.Z. Liu, T. Liu, X. Feng, N. Yang, H.F. Zhou, Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J. Recept. Signal Transduct. Res. 35(6), 600–604 (2015)CrossRef Y. Sun, W.Z. Liu, T. Liu, X. Feng, N. Yang, H.F. Zhou, Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J. Recept. Signal Transduct. Res. 35(6), 600–604 (2015)CrossRef
26.
Zurück zum Zitat M. Burotto, V.L. Chiou, J.M. Lee, E.C. Kohn, The MAPK pathway across different malignancies: a new perspective. Cancer 120(22), 3446–3456 (2014)CrossRef M. Burotto, V.L. Chiou, J.M. Lee, E.C. Kohn, The MAPK pathway across different malignancies: a new perspective. Cancer 120(22), 3446–3456 (2014)CrossRef
27.
Zurück zum Zitat U.A. Germann, B.F. Furey, W. Markland, R.R. Hoover, A.M. Aronov, J.J. Roix, M. Hale, D.M. Boucher, D.A. Sorrell, G. Martinez-Botella, M. Fitzgibbon, P. Shapiro, M.J. Wick, R. Samadani, K. Meshaw, A. Groover, G. DeCrescenzo, M. Namchuk, C.M. Emery, S. Saha, D.J. Welsch, Targeting the MAPK signaling pathway in cancer: Promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (Ulixertinib). Mol. Cancer Ther. 16(11), 2351–2363 (2017) U.A. Germann, B.F. Furey, W. Markland, R.R. Hoover, A.M. Aronov, J.J. Roix, M. Hale, D.M. Boucher, D.A. Sorrell, G. Martinez-Botella, M. Fitzgibbon, P. Shapiro, M.J. Wick, R. Samadani, K. Meshaw, A. Groover, G. DeCrescenzo, M. Namchuk, C.M. Emery, S. Saha, D.J. Welsch, Targeting the MAPK signaling pathway in cancer: Promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (Ulixertinib). Mol. Cancer Ther. 16(11), 2351–2363 (2017)
28.
Zurück zum Zitat T.C. Hamilton, R.C. Young, W.M. McKoy, K.R. Grotzinger, J.A. Green, E.W. Chu, J. Whang-Peng, A.M. Rogan, W.R. Green, R.F. Ozols, Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43(11), 5379–5389 (1983)PubMed T.C. Hamilton, R.C. Young, W.M. McKoy, K.R. Grotzinger, J.A. Green, E.W. Chu, J. Whang-Peng, A.M. Rogan, W.R. Green, R.F. Ozols, Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43(11), 5379–5389 (1983)PubMed
29.
Zurück zum Zitat J. Crow, S. Atay, S. Banskota, B. Artale, S. Schmitt, A.K. Godwin, Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget 8(7), 11917–11936 (2017)CrossRef J. Crow, S. Atay, S. Banskota, B. Artale, S. Schmitt, A.K. Godwin, Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget 8(7), 11917–11936 (2017)CrossRef
30.
Zurück zum Zitat J. Hirst, H.B. Pathak, S. Hyter, Z.Y. Pessetto, T. Ly, S. Graw, D.C. Koestler, A.J. Krieg, K.F. Roby, A.K. Godwin, Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties. Cancer Res. 78(15), 4370–4385 (2018) J. Hirst, H.B. Pathak, S. Hyter, Z.Y. Pessetto, T. Ly, S. Graw, D.C. Koestler, A.J. Krieg, K.F. Roby, A.K. Godwin, Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties. Cancer Res. 78(15), 4370–4385 (2018)
31.
Zurück zum Zitat S. Domcke, R. Sinha, D.A. Levine, C. Sander, N. Schultz, Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, Article number: 2126 (2013)CrossRef S. Domcke, R. Sinha, D.A. Levine, C. Sander, N. Schultz, Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, Article number: 2126 (2013)CrossRef
32.
Zurück zum Zitat B. Stordal, K. Timms, A. Farrelly, D. Gallagher, S. Busschots, M. Renaud, J. Thery, D. Williams, J. Potter, T. Tran, G. Korpanty, M. Cremona, M. Carey, J. Li, Y. Li, O. Aslan, J.J. O'Leary, G.B. Mills, B.T. Hennessy, BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol. Oncol. 7(3), 567–579 (2013)CrossRef B. Stordal, K. Timms, A. Farrelly, D. Gallagher, S. Busschots, M. Renaud, J. Thery, D. Williams, J. Potter, T. Tran, G. Korpanty, M. Cremona, M. Carey, J. Li, Y. Li, O. Aslan, J.J. O'Leary, G.B. Mills, B.T. Hennessy, BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol. Oncol. 7(3), 567–579 (2013)CrossRef
33.
Zurück zum Zitat A. Rot, U.H. von Andrian, Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891–928 (2004)CrossRef A. Rot, U.H. von Andrian, Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891–928 (2004)CrossRef
34.
Zurück zum Zitat Z. Cao, B. Fu, B. Deng, Y. Zeng, X. Wan, L. Qu, Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma. Cancer Cell Int. 14(1), 86 (2014)CrossRef Z. Cao, B. Fu, B. Deng, Y. Zeng, X. Wan, L. Qu, Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma. Cancer Cell Int. 14(1), 86 (2014)CrossRef
35.
Zurück zum Zitat P.L. Kuo, K.H. Shen, S.H. Hung, Y.L. Hsu, CXCL1/GROalpha increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-kappaB/HDAC1 epigenetic regulation. Carcinogenesis 33(12), 2477–2487 (2012)CrossRef P.L. Kuo, K.H. Shen, S.H. Hung, Y.L. Hsu, CXCL1/GROalpha increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-kappaB/HDAC1 epigenetic regulation. Carcinogenesis 33(12), 2477–2487 (2012)CrossRef
36.
Zurück zum Zitat N. Wang, W. Liu, Y. Zheng, S. Wang, B. Yang, M. Li, J. Song, F. Zhang, X. Zhang, Q. Wang, Z. Wang, CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling. Cell Death Dis. 9(9), 880 (2018)CrossRef N. Wang, W. Liu, Y. Zheng, S. Wang, B. Yang, M. Li, J. Song, F. Zhang, X. Zhang, Q. Wang, Z. Wang, CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling. Cell Death Dis. 9(9), 880 (2018)CrossRef
37.
Zurück zum Zitat K.I. Amiri, A. Richmond, Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog. Nucleic Acid Res. Mol. Biol. 74, 1–36 (2003)CrossRef K.I. Amiri, A. Richmond, Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog. Nucleic Acid Res. Mol. Biol. 74, 1–36 (2003)CrossRef
38.
Zurück zum Zitat P. Jiang, X. Li, C.B. Thompson, Z. Huang, F. Araiza, R. Osgood, G. Wei, M. Feldmann, G.I. Frost, H.M. Shepard, Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res. 32(4), 1203–1212 (2012)PubMed P. Jiang, X. Li, C.B. Thompson, Z. Huang, F. Araiza, R. Osgood, G. Wei, M. Feldmann, G.I. Frost, H.M. Shepard, Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res. 32(4), 1203–1212 (2012)PubMed
39.
Zurück zum Zitat J. Kzhyshkowska, M. Bizzarri, R. Apte, N. Cherdyntseva, Editorial: Targeting of cancer cells and tumor microenvironment: Perspectives for personalized therapy. Curr. Pharm. Des. 23(32), 4703–4704 (2017) J. Kzhyshkowska, M. Bizzarri, R. Apte, N. Cherdyntseva, Editorial: Targeting of cancer cells and tumor microenvironment: Perspectives for personalized therapy. Curr. Pharm. Des. 23(32), 4703–4704 (2017)
40.
Zurück zum Zitat S.R. Singh, P. Rameshwar, P. Siegel, Targeting tumor microenvironment in cancer therapy. Cancer Lett. 380(1), 203–204 (2016)CrossRef S.R. Singh, P. Rameshwar, P. Siegel, Targeting tumor microenvironment in cancer therapy. Cancer Lett. 380(1), 203–204 (2016)CrossRef
41.
Zurück zum Zitat S.J. Burke, D. Lu, T.E. Sparer, T. Masi, M.R. Goff, M.D. Karlstad, J.J. Collier, NF-kappaB and STAT1 control CXCL1 and CXCL2 gene transcription. Am. J. Physiol. Endocrinol. Metab. 306(2), E131–E149 (2014)CrossRef S.J. Burke, D. Lu, T.E. Sparer, T. Masi, M.R. Goff, M.D. Karlstad, J.J. Collier, NF-kappaB and STAT1 control CXCL1 and CXCL2 gene transcription. Am. J. Physiol. Endocrinol. Metab. 306(2), E131–E149 (2014)CrossRef
42.
Zurück zum Zitat G. Yang, D.G. Rosen, G. Liu, F. Yang, X. Guo, X. Xiao, F. Xue, I. Mercado-Uribe, J. Huang, S.H. Lin, G.B. Mills, J. Liu, CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res. 16(15), 3875–3886 (2010)CrossRef G. Yang, D.G. Rosen, G. Liu, F. Yang, X. Guo, X. Xiao, F. Xue, I. Mercado-Uribe, J. Huang, S.H. Lin, G.B. Mills, J. Liu, CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res. 16(15), 3875–3886 (2010)CrossRef
43.
Zurück zum Zitat D. Wang, H. Sun, J. Wei, B. Cen, R.N. DuBois, CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77(13), 3655–3665 (2017) D. Wang, H. Sun, J. Wei, B. Cen, R.N. DuBois, CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77(13), 3655–3665 (2017)
Metadaten
Titel
Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation
verfasst von
Geun-Young Park
Harsh B. Pathak
Andrew K. Godwin
Youngjoo Kwon
Publikationsdatum
10.09.2020
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 1/2021
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00554-0

Weitere Artikel der Ausgabe 1/2021

Cellular Oncology 1/2021 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …